Please assess the completion status of the following clinical trial:

Trial Title: Small Particle Steroids in Refractory Asthma

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Age 18-80~* ACQ \>1.5 or a requirement for oral steroids twice a year or more~* High dose inhaled steroid (\>1000mcg BDP or equivalent)~* Treatment with or unsuccessful trial of:~  * long-acting beta agonist~ * leukotriene antagonist~* Sputum eosinophil count \>3% despite high dose inhaled steroid or \>2% with serum eosinophils \>0.4x10exp9/l~* Clinical response to 2 weeks of oral prednisolone: (any one)~  * reduction in ACQ by 0.5 or more~ * increase in FEV1 by 200ml~ * normalisation of exhaled nitric oxide or reduction of \>25ppb~Exclusion Criteria:~* Current smoker, or ex-smoker for \<12 months~* Current treatment with an extrafine steroid inhaler~* Respiratory infection within the last 4 weeks~* Pregnancy or lactation~* Poor compliance with usual asthma medication~* Clinical diagnosis of significant bronchiectasis~* Use of a medication which may interact with ciclesonide:~  * ketoconazole or itraconazole~ * ritonavir, nelfinavir

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- Ciclesonide (Type: ACTIVE_COMPARATOR): Ciclesonide 320 microgrammes twice daily
- Placebo (Type: PLACEBO_COMPARATOR): Placebo 2 inhalations twice daily

Based on this trial design, predict the completion outcome and termination type (if applicable).